Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RSV Inhibitor
AZ-27 is a selective inhibitor of respiratory syncytial virus (RSV) by targeting its polymerase activity. This compound exhibits the ability to differentially suppress various RSV polymerase functions at the promoter level, effectively inhibiting the early stages of mRNA transcription and genome replication. AZ-27 is suitable for research applications focused on understanding RSV pathogenesis and developing antiviral strategies. -
RSV L protein Inhibitor
AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies. -
RSV Inhibitor
RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis. -
RSV Inhibitor
A 33903 is a selective inhibitor of respiratory syncytial virus (RSV) replication. It demonstrates significant antiviral activity against RSV, making it a valuable tool for researchers studying RSV infections and related therapeutic interventions. This reagent can facilitate investigations into viral pathogenesis and the development of antiviral strategies. -
RSV Inhibitor
4,5-O-Dicaffeoyl quinic acid methyl ester is a potent antiviral agent specifically targeting respiratory syncytial virus (RSV). It exhibits strong inhibitory activity with an IC50 value of 0.63 μg/mL, indicating effective suppression of viral replication. The compound's safety profile is substantiated by a CC50 of 118.68 μg/mL, supporting its potential use in research applications focused on RSV-related therapeutic strategies. -
SARS-CoV-2 3CL Protease Inhibitor
Ensitrelvir is a selective, non-covalent, and non-peptidic inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 13 nM. This compound has demonstrated significant antiviral activity against SARS-CoV-2, making it a valuable tool for research into COVID-19 treatments. It is particularly applicable in studies focused on viral replication and therapeutic interventions targeting coronavirus proteases. -
SARS-CoV-2 Inhibitor
Simnotrelvir is a potent inhibitor of SARS-CoV-2 3CLpro, demonstrating an IC50 value of 0.022 µM. This compound exhibits significant antiviral activity against SARS-CoV-2, making it a valuable tool in research focusing on COVID-19 treatment and prevention strategies. Its efficacy in inhibiting viral replication positions it as a critical reagent for investigations into therapeutic options for coronavirus infections. -
SARS-CoV-2 3CL Protease Inhibitor
Ensitrelvir fumarate is a non-covalent, non-peptidic inhibitor targeting the SARS-CoV-2 3CL protease, exhibiting an IC50 of 13 nM. This compound plays a critical role in the inhibition of viral replication by blocking a key enzymatic function essential for SARS-CoV-2 maturation. It is primarily utilized in research applications related to COVID-19 therapeutic development and the exploration of antiviral strategies. -
SARS-CoV-2 Mpro Inhibitor
(±)-Alliin is a compound derived from garlic, recognized for its potential inhibitory effects on the main protease of SARS-CoV-2 (Mpro). This compound demonstrates antiviral activity, making it a candidate for research aimed at understanding and combating SARS-CoV-2 replication and infection mechanisms. Its application in biochemical studies can contribute to the development of therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
Leritrelvir is an orally active inhibitor of the SARS-CoV-2 main protease, displaying a slow-tight binding mechanism with a Ki value of 8.6 nM. This compound is valuable for research focused on therapeutic strategies against COVID-19, demonstrating potential in the development of antiviral agents aimed at mitigating SARS-CoV-2 replication. Its efficacy as a protease inhibitor makes it a significant candidate for studying protease-related pathways and antiviral drug design. -
SARS-CoV-2 3C-like protease (3CLpro) Inhibitor
Secutrelvir is a potent inhibitor of the SARS-CoV-2 3C-like protease (3CLpro), demonstrating IC50 values of 0.655 nM and 0.697 nM. By forming a reversible covalent bond with the catalytic cysteine C145, Secutrelvir effectively inhibits viral replication, making it a valuable tool in combating SARS-CoV-2. Its efficacy against various SARS-CoV-2 variants supports its potential applications in research focused on coronavirus disease 2019 (COVID-19). -
SARS-CoV-2 Inhibitor
Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 24 nM against wild-type SARS-CoV-2 Mpro. By inhibiting viral polyprotein processing, it effectively disrupts viral replication. Pomotrelvir demonstrates broad antiviral activity against various SARS-CoV-2 variants, including Omicron, and shows an additive effect when co-administered with nucleoside analogs targeting viral RNA synthesis. It is primarily utilized in the research and development of antiviral therapeutics for COVID-19 caused by SARS-CoV-2 and its variants. -
SARS-CoV-2 Inhibitor
Iscartrelvir is a non-covalent inhibitor that targets the 3CLpro protein of SARS-CoV-2. This compound demonstrates potent inhibitory activity against multiple SARS-CoV-2 variants, including Alpha, Beta, Gamma, Delta, Lambda, and Omicron, as well as two other coronaviruses, SARS-CoV and MERS-CoV. Iscartrelvir is valuable for research applications focused on antiviral strategies and the study of coronavirus proteases. -
SARS-CoV-2 Membrane Protein Inhibitor
CIM-834 is an orally bioavailable inhibitor targeting the SARS-CoV-2 membrane protein. It effectively disrupts the assembly of infectious viral particles while preserving viral RNA synthesis. In preclinical studies, CIM-834 has demonstrated a capability to reduce viral titers in lung tissues of SCID mice and prevent the transmission of SARS-CoV-2 among Syrian hamsters. Additionally, it exhibits inhibitory effects on the replication of both SARS-CoV-2 variants and SARS-CoV, making it relevant for COVID-19 research applications. -
SARS-CoV-2 Inhibitor
MPI60 is a potent inhibitor of SARS-CoV-2 main protease (MPro), demonstrating significant antiviral activity and low cellular cytotoxicity. This compound exhibits high metabolic stability in vitro, making it a valuable tool for SARS-CoV-2 research and therapeutic development. Researchers can utilize MPI60 to explore the molecular mechanisms of viral replication and potential intervention strategies. -
SARS-CoV Inhibitor
GS-621763 is an orally bioavailable prodrug of GS-441524 that serves as a potent inhibitor of SARS-CoV-2. It demonstrates significant antiviral activity, effectively reducing viral load to undetectable levels in ferrets infected with SARS-CoV-2. This compound is valuable for research applications related to coronavirus pathogenesis and therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
Cichoriin is a potent inhibitor of SARS-CoV-2, targeting viral replication and entry into host cells. It demonstrates significant antiviral activity, making it a valuable candidate for research into therapies for severe COVID-19. This compound may facilitate studies on the pathogenesis of the virus and the development of effective treatment strategies. -
SARS-CoV-2 MPro Inhibitor
Mpro inhibitor N3 is a potent inhibitor of the SARS-CoV-2 main protease (MPro), demonstrating an EC50 value of 16.77 µM. This compound exhibits antiviral activity not only against SARS-CoV-2 but also against other coronaviruses, including HCoV-229E, FIPV, IBV, and MHV-A59. Its ability to inhibit viral replication makes it a valuable tool for research in antiviral drug development and coronavirus disease studies. -
SARS-CoV-2 Inhibitor
AT-9010 tetrasodium is a potent inhibitor of the nucleotidyltransferase (NiRAN) domain, crucial for the replication of SARS-CoV-2. This triphosphate active metabolite of AT-527 demonstrates significant antiviral activity by disrupting viral replication processes. Its application is primarily focused on research related to SARS-CoV-2 and the development of therapeutic interventions for COVID-19. -
SARS-CoV-2 PLpro Inhibitor
PF-07957472 is an orally active inhibitor of the SARS-CoV-2 papain-like protease (PLpro). It demonstrates significant antiviral activity, evidenced by an EC50 of 13.9 nM in SARS-CoV-2 infected normal human bronchial epithelial (NHBE) cells. Additionally, PF-07957472 exhibits protective effects in a mouse model adapted for COVID-19, making it a valuable reagent for studying antiviral mechanisms and therapeutic applications related to SARS-CoV-2 infection. -
SARS-CoV Replication Inhibitor
SSAA09E2 is an inhibitor of SARS-CoV replication, specifically targeting the early interactions between the SARS spike protein (S) and its receptor, Angiotensin Converting Enzyme-2 (ACE2). This compound exhibits significant antiviral activity, making it a valuable tool for research into therapeutic strategies against SARS-CoV infections. Its application in studying viral entry mechanisms and potential treatments provides critical insights into coronavirus-related diseases. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-13 is a potent inhibitor of SARS-CoV-2 with a reported IC50 of 0.057 μM. As a niclosamide analogue, it demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may lead to improved bioavailability and longer half-life upon oral administration. This compound is valuable for research applications focused on antiviral therapies and understanding SARS-CoV-2 inhibition mechanisms. -
Clk1 Inhibitor
CLK1-IN-2 is a potent and metabolically stable inhibitor of CLK1, exhibiting a selectivity for its target with an IC50 value of 1.7 nM. This compound is valuable for research applications focusing on tumor biology, Duchenne muscular dystrophy, and viral infections, including HIV-1 and influenza. CLK1-IN-2 facilitates the study of cellular mechanisms and therapeutic interventions related to these diseases. -
CLK Inhibitor
KH-CB19 is a selective inhibitor of CLK (cdc2-like kinase) with an IC50 of 19.7 nM for CLK1 and 530 nM for CLK3. This compound exhibits antiviral properties, demonstrated by its ability to hinder influenza virus replication, with an IC50 value of 13.6 μM. KH-CB19 serves as a valuable tool for research into CLK-related pathways and antiviral drug development. -
SARS-CoV-2 Inhibitor
SARS-CoV-2 nsp14-IN-3 is an inhibitor of the SARS-CoV-2 N7-Methyltransferase, demonstrating an IC50 value of 3.5 μM. This compound is designed to interfere with the viral methylation process, which is crucial for viral replication and evasion of host immune responses. It serves as a valuable tool in antiviral research and the development of therapeutic strategies targeting SARS-CoV-2. -
SARS-CoV Inhibitor
SARS-CoV-2-IN-7 is a potent inhibitor of the SARS-CoV virus, demonstrating significant antiviral activity with an IC50 value of 844 nM in SARS-CoV-2-infected Vero E6 cells. This compound is primarily utilized in research applications aimed at understanding viral replication processes and developing effective therapeutics against SARS-CoV-2. Its efficacy makes it a valuable tool for studying COVID-19 and potential antiviral strategies. -
SARS-CoV Inhibitor
Bonducellpin D is a furanoditerpenoid lactone that acts as an inhibitor of SARS-CoV and MERS-CoV main proteases (Mpro). With Ki values of 467.11 nM and 284.86 nM for SARS-CoV and MERS-CoV, respectively, it demonstrates broad-spectrum antiviral activity. Additionally, Bonducellpin D exhibits moderate anti-cancer activity in vitro, making it a valuable compound for research into both viral inhibition and cancer therapeutics. -
SARS-CoV Inhibitor
SSAA09E3 is a SARS-CoV entry inhibitor that effectively blocks the entry of SARS/HIV pseudotyped viruses, demonstrating an EC50 of 9.7 μM in 293T cells. Additionally, it has shown significant antiviral activity against SARS-CoV infection in Vero cells, with an EC50 of 0.15 μM. This compound is valuable for research applications aimed at understanding viral entry mechanisms and developing antiviral strategies against SARS-CoV. -
SARS-CoV-2 Inhibitor
AT-9010 triethylamine is a tri-phosphate active metabolite of AT-527 that functions as a potent inhibitor of the NiRAN enzyme, an essential target for viral replication in SARS-CoV-2. It exhibits significant antiviral activity by effectively inhibiting the replication of SARS-CoV-2, making it a valuable tool for research on COVID-19 and potential therapeutic strategies against coronavirus infections. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-15 is a potent inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.49 μM. This niclosamide analogue demonstrates enhanced stability in human plasma and liver S9 enzyme assays compared to its predecessor, which may improve its bioavailability and half-life upon oral administration. SARS-CoV-2-IN-15 is suitable for research applications focused on antiviral drug development and the elucidation of SARS-CoV-2 infection mechanisms. -
SARS-CoV-2 Inhibitor
Cleistanthin B is a potent inhibitor of SARS-CoV-2, demonstrating anti-viral activity with an EC50 of 6.51 µM in Vero cells. This orally active arylnaphthalene lignan lactone glycoside also exhibits notable antitumor, diuretic, and antihypertensive properties in vivo, making it a versatile compound for various research applications in virology and pharmacology. -
SARS-CoV-2 PLpro Inhibitor
GZNL-P36 is a potent inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM, demonstrating effective inhibition of SARS-CoV and its variants with EC50 values ranging from 58.2 nM to 2.66 µM. In pharmacokinetic studies conducted in CD-1 mice, GZNL-P36 achieved a peak plasma concentration (Cmax) of 549 ng/mL, a half-life (T1/2) of 1.45 hours, and a bioavailability of 74.7%. This compound exhibits notable antiviral activity in SARS-CoV-2 XXB.1 infections, positioning it as a valuable tool in therapeutic research against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-78 is an inhibitor of the nsp14 protein of SARS-CoV-2, specifically targeting its N7 methyltransferase activity. This compound demonstrates significant antiviral properties and is valuable for research applications in understanding and mitigating SARS-CoV-2 infection. Its mechanism of action makes it a pertinent tool for studying viral replication and pathogenesis, as well as the development of potential therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
ZINC000104379474 is a potent inhibitor of SARS-CoV-2 endoribonuclease. It exhibits significant antiviral activity, making it a valuable tool in the study of SARS-CoV-2 replication mechanisms. This compound is particularly relevant for research focused on COVID-19 therapeutics and the development of novel antiviral strategies. -
SARS-CoV-2 Nsp14 Inhibitor
SARS-CoV-2 nsp14-IN-2 is a selective inhibitor of SARS-CoV-2 Nsp14 methyltransferase, exhibiting an IC50 value of 0.093 µM. This compound demonstrates significant antiviral activity and is stable in plasma and liver S9 fractions. SARS-CoV-2 nsp14-IN-2 is valuable for research applications focusing on COVID-19 and the exploration of therapeutic strategies targeting viral replication mechanisms. -
SARS-CoV Inhibitor
SARS-CoV MPro-IN-1 is a covalent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 of 40 nM. This compound demonstrates significant anti-SARS-CoV-2 activity in cell culture, with an EC50 of 0.33 μM. SARS-CoV MPro-IN-1 is suitable for research applications focused on COVID-19 and related viral pathogenesis. -
SARS-CoV-2 Inhibitor
10-Hydroxyaloin A is a potent inhibitor of SARS-CoV-2, specifically targeting the main protease (Mpro) of the virus. This compound demonstrates significant binding affinity to the active site of Mpro, which is crucial for viral replication. 10-Hydroxyaloin A is of particular interest in research applications focused on antiviral drug development and understanding the mechanisms of SARS-CoV-2 inhibition. -
SARS-CoV-2 3CLpro Inhibitor
3CPLro-IN-1 is a potent, orally active inhibitor of the SARS-CoV-2 3CLpro with an IC50 of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) plays a critical role in viral replication, making it a significant target for therapeutic intervention against COVID-19. This compound is suitable for research applications focused on developing antiviral strategies and studying the mechanistic pathways of viral replication. -
SARS-CoV-2 Inhibitor
Amb929 is a selective inhibitor targeting the nsp3 protein of SARS-CoV-2, demonstrating significant antiviral activity. It effectively inhibits SARS-CoV-2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM and has a moderate cytotoxicity profile, with a CC50 of 281 µM. Additionally, Amb929 shows effectiveness in suppressing viral replication in Human Airway Epithelium (HAE) models, making it a valuable tool for research on COVID-19 and therapeutic development. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2-IN-35 is a potent inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrating a Ki value of 12.1 nM. This compound serves as a valuable tool for investigating the antiviral mechanisms and therapeutic strategies in COVID-19 research. Its oral bioactivity allows for flexible in vivo studies, facilitating the exploration of potential treatments against SARS-CoV-2. -
SARS-CoV-2Inhibitor
SARS-CoV-2-IN-43 is a potent inhibitor of SARS-CoV-2 replication, displaying significant antiviral activity. This compound is valuable for research applications aimed at understanding and mitigating SARS-CoV-2 infection. Its mechanism of action targets key processes in viral replication, making it a crucial tool for studies in virology and therapeutic development against COVID-19. -
SARS-CoV-2 Mpro Inhibitor
AB-343 is a selective covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, exhibiting an IC50 of 8 nM and a Ki of 2.8 nM. This compound effectively inhibits the Mpro of SARS-CoV-2 and other coronaviruses, demonstrating activity against certain resistant variants. AB-343 is suitable for research applications focused on therapeutic strategies for coronavirus infection-related diseases. -
Macropinocytosis inhibitor
Virapinib is a potent macropinocytosis inhibitor that demonstrates significant antiviral activity. It effectively inhibits viral entry of a broad range of viruses, including SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, while also enhancing Dengue Virus infection. By obstructing macropinocytosis, Virapinib reduces syncytium formation in SARS-CoV-2-infected cells and hinders the cellular entry of SARS-CoV-2 variants. This compound is valuable for research focused on viral pathogenesis and therapeutic evaluations related to COVID-19 and other viral infections. -
SARS-CoV-2 Mpro Inhibitor
SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent and selective irreversible inhibitor of the SARS-CoV-2 main protease (Mpro), demonstrated by an IC50 of 116 nM. This compound serves as a valuable tool in research targeting SARS-CoV-2, facilitating investigations into viral replication and pathogenesis. Its mechanistic profile makes it suitable for studies aimed at developing antiviral strategies against COVID-19. -
SARS-CoV-2 Mpro Iinhibitor
GC-78-HCl is a nonpeptidic inhibitor of the SARS-CoV-2 main protease (Mpro), exhibiting an IC50 of 0.19 μM. This compound demonstrates significant antiviral activity and has been characterized by favorable pharmacokinetic properties. It is a valuable reagent for research aimed at exploring therapeutic strategies against SARS-CoV-2 and related coronaviruses. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-66 is a vitamin K derivative and a potent inhibitor of SARS-CoV-2. It exhibits an EC50 value of 70.8 μM in Vero E6/TMPRSS2 cell lines, demonstrating significant antiviral activity. This compound can be utilized in research focused on the development of therapeutic strategies against SARS-CoV-2 infection. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-100 is a potent inhibitor targeting SARS-CoV-2, exhibiting broad-spectrum antiviral activity against multiple variants of the virus. This compound demonstrates synergistic effects when used in combination with Nirmatrelvir, potentially mitigating the risk of antiviral drug resistance. It is suitable for research applications focused on COVID-19 therapeutics and viral replication studies. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-76 is a specific inhibitor of the nsp14 viral cap N7 methyltransferase and PLpro, targeting the severe acute respiratory syndrome coronavirus (SARS-CoV-2). This compound demonstrates significant antiviral activity by disrupting key enzymatic processes essential for viral replication. It is a valuable tool for research applications focused on understanding SARS-CoV-2 pathogenesis and developing therapeutic strategies against COVID-19. -
SARS-CoV-2 3CLpro Inhibitor
SARS-CoV-2-IN-80 is a potent inhibitor of the SARS-CoV-2 3CL protease, exhibiting an IC50 value of 0.964 µM. This compound demonstrates strong antiviral activity, making it a valuable tool for research aimed at unraveling the mechanisms of SARS-CoV-2 replication and pathogenesis. It is suitable for studies focused on developing therapeutic strategies against COVID-19. -
SARS-CoV-2 Inhibitor
SARS-CoV-2-IN-75 is a chloroacetamide-based inhibitor targeting SARS-CoV-2. This compound demonstrates significant antiviral activity, inhibiting cellular replication of SARS-CoV-2 with an EC68 value of 3 μM. It is relevant for research applications focused on understanding viral mechanisms and developing therapeutic strategies against COVID-19.
